Lipidor updates on Phase III clinical study of psoriasis candidate AKP02
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
STOCKHOLM, Sweden, 29 September 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that it has updated the company’s schedule for the Phase III study of AKP02 for the treatment of psoriasis. After a minor delay from the company's CRO partner Cadila, the data is estimated to be available for analysis by our statistical partner in mid-October. The company assesses that the study's topline results can be presented during the second half of October.
The primary objective of the Phase III study is to demonstrate good therapeutic efficacy for the treatment of mild to moderate psoriasis on both the body and the scalp. The psoriasis candidate AKP02 combines calcipotriol and betamethasone dipropionate and is based on Lipidor's patented AKVANO® technology. Lipidor has chosen to compare the sprayable drug candidate AKP02 with Enstilar, which is one of the market-leading preparations for topical treatment in psoriasis. AKP02 contains the same combination of active substances as Enstilar. The aim with AKP02 is to offer a patient-friendly, spray-based form of treatment for mild to moderate psoriasis.
Publication
The information was provided for publication by Lipidor’s CEO on 29 September 2022 at 8.00am CEST.